Project Grant R01HL174616
Award Date
8/16/24
Completion Date
7/31/28
Dollars Obligated
$705K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $480,990 to the University of Illinois for a research project focused on accelerating alveolar epithelial regeneration to treat acute respiratory distress syndrome (ARDS). The key objectives are to investigate the role of "aerocytes", a newly identified capillary endothelial cell population, in regulating alveolar...
This Project Grant award of $775,992.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through Tregs impacts their immunomodulatory and tissue...
This $186,408 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to evaluate CD14 as a potential therapeutic target for acute respiratory distress syndrome (ARDS). The project aims to: 1) determine the effects of the CD14-blocking antibody IC14 on cellular targets through blood leukocyte RNA sequencing analysis, 2) examine the relationship between the CD14-pathway biomarker presepsin...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,220,472.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on using B cell therapy to ameliorate pulmonary and neurological sequelae in survivors of acute respiratory distress syndrome (ARDS). The key aims are to study the efficiency of B cell homing to the lungs and brain, identify the immunomodulatory...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $189,000 to the University of Colorado-Denver to investigate the role of aldehyde dehydrogenase 2 (ALDH2) in pulmonary fibrosis following acute lung injury and acute respiratory distress syndrome (ARDS). The 2-year research project aims to elucidate the mechanisms by which ALDH2 impacts fibrogenesis in lung cells and evaluate the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $1,147,992 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at advancing precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The key focus is on deeply phenotyping human samples to understand the functional immune response and pathogen drivers of...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This Project Grant award, identified as R01HL170118, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, totaling $495,159.00, will fund research to investigate the role of the protein CARMIL1 in regulating endothelial cell barrier function and its potential impact on acute respiratory distress syndrome (ARDS). The study, to be conducted by the University of Illinois, will use...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $656,988 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to study the role of HMGB1 in the lung's response to bacterial injury. The objective is to develop a therapeutic strategy to replace a failed component of the macrophage lung injury response and enable healing in patients with...
This federal Project Grant award of $200,502 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project led by Dr. Narges Alipanah-Lechner at the University of California, San Francisco (UCSF). The project aims to identify metabolite and protein drivers of the evolution of Acute Respiratory Distress Syndrome (ARDS) subtypes, specifically the hyper-inflammatory and hypo-inflammatory forms. The research will utilize comprehensive...